Researchers have identified a new biomarker for rheumatoid arthritis that could help with earlier diagnosis and treatment.
A novel biomarker could make it easier for physicians to diagnose rheumatoid arthritis early, thereby improving patients' prospects. The best results come when conventional antibody testing is combined with the new biomarker.
Myriad Genetics paid $270 million for Crescendo Bioscience in February, and now a new study affirms the clinical viability of Crescendo's Vectra DA, a protein-based test designed to assess a patient's rheumatoid arthritis disease progression and activity.
Inova Diagnostics once again has its sights on rheumatoid arthritis-detecting technology, this week acquiring a novel platform developed at Hasselt University designed to identify autoantibody biomarkers for the debilitating condition.
With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space.
Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...
The FDA has approved Simponi in combination with methotrexate to treat moderately to severely active rheumatoid arthritis. The company points out that an estimated 1.3 million Americans and more than 23.5 million people worldwide suffer from RA.
Crescendo Bioscience won Medicare coverage for its rheumatoid arthritis molecular diagnostic, a major milestone and pivotal move in its bid to expand the test's market reach.
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.